Trial Profile
An Open-label, Randomized Study to Compare the Efficacy and Safety of P1101 Plus Tenofovir Alafenamide With or Without Ursodeoxycholic Acid in Patients With Chronic Hepatitis B and Hepatitis D Virus Co-Infection
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Jan 2023
Price :
$35
*
At a glance
- Drugs Ropeginterferon alfa-2b (Primary) ; Tenofovir alafenamide (Primary) ; Ursodeoxycholic acid (Primary)
- Indications Hepatitis B; Hepatitis D
- Focus Pharmacodynamics
- 27 Dec 2022 Planned initiation date changed from 31 Aug 2022 to 24 Feb 2023.
- 25 Jul 2022 New trial record